Nucleix secures $55M in funding for lung cancer test

April 7, 2021 -- Liquid biopsy company Nucleix has secured $55 million to advance Lung EpiCheck, an early detection lung cancer test based on methylation technology.

Nucleix will use the financing to continue to advance its methylation technology and the blood-based assay. The test analyzes subtle, disease-specific changes in DNA methylation markers in patients, specifically current and former smokers.

Nucleix showcases Bladder EpiCheck at EAU 2020
Liquid biopsy firm Nucleix touted results for its methylation-based Bladder EpiCheck urine test in two presentations at the 2020 European Association...
Nucleix highlights data for urine test in detecting bladder cancer
Liquid biopsy firm Nucleix said that its methylation-based Bladder EpiCheck urine test produced strong results for detecting high-risk, non-muscle invasive...

Copyright © 2021

Last Updated ls 4/7/2021 2:47:48 PM